News
FDA delivers second complete response letter to Intarcia for ITCA-650 implant—a small, osmotic pump to treat type 2 diabetes.
The FDA has delivered a second Complete Response Letter to Intarcia for its ITCA-650 implant—a small, osmotic pump designed to be delivered under the skin and deliver a continuous, six-month dose of the GLP-1 agonist exenatide, also sold as Byetta and Bydureon. Typically a twice-daily or once-weekly injection, Intarcia’s formulation aims to stabilize the drug to keep it viable at human body temperature for extended periods of time.
Condition: Diabetes Type 2
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins